7Baggers

Cronos Group Inc
(NASDAQ:CRON) 

CRON stock logo

Cronos Group Inc. operates as a cannabinoid company. It manufactures, markets, and distributes hemp-derived supplements and cosmetic products through e-commerce, retail, and hospitality partner channels under the Lord Jones and Happy Dance brands in the United States. The company is also involved in...

Founded: 2012
Full Time Employees: 631
Sector: Healthcare
Industry: Drug Manufacturers-Specialty & Generic
CannabisCanadian
Share this website to your friends
• Market Cap:
• Exchange:
• Shs Outstanding:
• Employees:
• Beta:
• Return on Equity (ROE) ttm:
• Return on Assets (ROA) ttm:
• EPS ttm:
• Book value per Share:
• Cash per Share:
• Current ast per Share:
• P/E ttm:
• P/E forward:
• P/E ttm high:
• P/E ttm low:
• P/S ttm:
• P/B ttm:
• P/FCF ttm:
• PEG ratio:
• Cash Ratio ttm:
• Quick Ratio ttm:
• Current Ratio ttm:
• Gross Mgn ttm:
• EBITDA Mgn ttm:
• Operating Mgn ttm:
• Net Income Mgn ttm:
• Trailing Div yield:
• Forward Div yield:
• Payout Ratio ttm:
• Ex-Dividend date:
• Target Price High:
• Target Price Low:
• Target Price Mean:
• Number of Analysts:
• Debt Ratio ttm:
• Debt to Equity ttm:
• Total Net Debt:
At a glance:
Bull Thesis:
Bear Thesis:
Main Competitors:
Moat:
Income Statements:
Quarterly
Annual
    Unit: USD2025-12-31 2025-09-30 2025-06-30 2025-03-31 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-11-12 2019-08-08 2019-05-09 2019-03-26 2018-11-13 2018-08-14 2018-05-15 
                                   
      net revenue, before excise taxes
    		33,744,500 48,828,000 44,252,000 41,898,000 41,182,000 46,594,000 38,678,000 35,367,000 34,006,000 33,912,000 25,798,000 27,203,000 29,912,000 26,584,000 28,554,000 29,406,000 14,523,000 24,590,000 18,848,000 14,654,000 19,956,000 13,621,000 11,432,000 9,344,000        
      yoy
    		-18.06% 4.79% 14.41% 18.47% 21.10% 37.40% 49.93% 30.01% 13.69% 27.57% -9.65% -7.49% 105.96% 8.11% 51.50% 100.67% -27.22% 80.53% 64.87% 56.83%            
      qoq
    		-30.89% 10.34% 5.62% 1.74% -11.62% 20.47% 9.36% 4.00% 0.28% 31.45% -5.16% -9.06% 12.52% -6.90% -2.90% 102.48% -40.94% 30.46% 28.62% -26.57% 46.51% 19.15% 22.35%         
      excise taxes
    		-8,230,500 -12,489,000 -10,797,000 -9,636,000 -10,881,000 -12,330,000 -10,916,000 -10,079,000 -10,091,000 -9,102,000 -6,777,000 -7,059,000 -7,025,000 -5,661,000 -5,493,000 -4,373,000 -5,599,000 -4,183,000 -3,226,000 -2,043,000 -2,910,000 -2,263,000 -1,549,000 -912,000 -639,000 -550,000 -515,000 -1,442,000    
      net revenue
    		-101,027,000 36,339,000 33,455,000 32,262,000 30,301,000 34,264,000 27,762,000 25,288,000 23,915,000 24,810,000 19,021,000 20,144,000 22,887,000 20,923,000 23,061,000 25,033,000 25,795,000 20,407,000 15,622,000 12,611,000 17,046,000 11,358,000 9,883,000 8,432,000 12,700,000 10,237,000 6,470,000 15,703,000    
      cost of sales
    		-52,730,000 17,501,000 18,865,000 18,528,000 19,494,000 30,341,000 21,070,000 20,805,000 21,913,000 20,124,000 15,922,000 17,764,000 23,121,000 19,766,000 18,941,000 18,107,000 23,852,000 21,137,000 19,445,000 15,574,000 16,913,000 12,895,000 9,774,000 6,946,000        
      inventory write-down
    		247,000 506,000 86,000   312,000 395,000  89,000 716,000         11,961,000  15,031,000  3,062,000 7,962,000        
      gross profit
    		-48,544,000 18,332,000 14,504,000 13,734,000 10,807,000 3,611,000 6,297,000 4,483,000 1,913,000 3,970,000 3,099,000 2,380,000 -234,000 1,157,000 4,120,000 6,926,000 1,943,000 -730,000  -2,963,000 -14,898,000 -1,537,000 -2,953,000 -6,476,000 -19,364,000 5,942,000 13,317,000 11,268,000 2,094,000 6,346,000 1,928,000 
      yoy
    		-549.19% 407.67% 130.33% 206.36% 464.92% -9.04% 103.19% 88.36% -917.52% 243.13% -24.78% -65.64% -112.04% -258.49%  -333.75% -113.04% -52.50%  -54.25% -23.06% -125.87% -122.17% -157.47% -1024.74% -6.37% 590.72%     
      qoq
    		-364.80% 26.39% 5.61% 27.08% 199.28% -42.66% 40.46% 134.34% -51.81% 28.11% 30.21% -1117.09% -120.22% -71.92% -40.51% 256.46% -366.16%   -80.11% 869.29% -47.95% -54.40% -66.56% -425.88% -55.38% 18.18% 438.11% -67.00% 229.15%  
      gross margin %
    		-143.86% 37.54% 32.78% 32.78% 26.24% 7.75% 16.28% 12.68% 5.63% 11.71% 12.01% 8.75% -0.78% 4.35% 14.43% 23.55% 13.38% -2.97% 0% -20.22% -74.65% -11.28% -25.83% -69.31% -Infinity% Infinity% Infinity% Infinity% Infinity% Infinity% Infinity% 
      operating expenses
    		                               
      sales and marketing
    		-14,635,000 5,301,000 5,347,000 4,565,000 6,413,000 5,528,000 4,330,000 5,332,000 6,367,000 5,296,000 5,297,000 5,872,000 5,765,000 5,923,000 5,582,000 5,012,000 10,653,000 10,821,000 13,209,000 10,254,000 13,537,000 7,236,000 6,504,000 7,112,000 6,057,000 5,358,000 1,500,000 4,111,000 598,000 364,000 586,000 
      research and development
    		-3,035,000 1,345,000 929,000 793,000 1,028,000 1,242,000 962,000 997,000 1,451,000 1,246,000 1,107,000 2,041,000 2,471,000 2,569,000 4,302,000 4,039,000 6,557,000 6,473,000 5,199,000 5,102,000 7,411,000 4,734,000 3,631,000 4,590,000 3,439,000 3,076,000 1,557,000 2,350,000    
      general and administrative
    		-28,431,000 9,254,000 10,536,000 9,309,000 12,080,000 12,760,000 12,767,000 8,907,000 9,802,000 14,366,000 13,451,000 12,379,000 14,638,000 17,167,000 17,005,000 22,368,000 19,613,000 32,546,000 22,417,000 21,906,000 19,481,000 18,860,000 18,437,000 23,759,000 21,270,000 15,176,000 9,611,000 17,421,000 4,820,000 4,219,000  
      restructuring costs
    		-1,012,000 212,000 768,000 555,000   547,000 83,000 101,000 1,423,000   455,000 524,000 1,270,000 3,084,000                
      share-based compensation
    		-5,789,000 2,333,000 1,381,000 2,088,000 2,187,000 2,262,000 2,236,000 2,015,000 1,933,000 1,957,000 2,331,000 2,551,000 4,548,000 4,265,000 2,616,000 3,686,000                
      depreciation and amortization
    		-1,704,000 354,000 867,000 496,000 464,000 1,098,000 1,016,000 1,123,000 529,000 1,457,000 1,533,000 1,533,000 1,608,000 1,713,000 1,411,000 1,293,000 1,455,000 1,251,000 1,043,000 735,000 620,000 886,000 684,000 687,000 907,000 675,000 470,000 1,256,000 330,000 323,000 285,000 
      impairment loss on long-lived assets
    		169,000 36,000    14,376,000  1,974,000        3,493,000 122,880,000 1,784,000              
      total operating expenses
    		-54,437,000 18,835,000 19,828,000 17,806,000 22,172,000 37,266,000 21,858,000 20,431,000 23,549,000 25,745,000 23,719,000 24,376,000 29,485,000 32,161,000 32,186,000 42,975,000 164,578,000 55,684,000 44,433,000 40,496,000 43,512,000 39,632,000 31,802,000 38,584,000 34,798,000 26,287,000 13,875,000 29,376,000 6,971,000 5,856,000 4,106,000 
      operating income
    		-2,474,750 -503,000 -5,324,000 -4,072,000 -11,365,000 -33,655,000 -15,561,000 -15,948,000 -21,636,000 -21,775,000 -20,620,000 -21,996,000 -29,719,000 -31,004,000 -28,066,000 -36,049,000 -162,635,000 -56,414,000 -60,217,000 -43,459,000 -58,410,000 -41,169,000 -34,755,000 -45,060,000 -54,162,000 -20,345,000 -558,000 -18,108,000 -4,877,000 490,000 -2,178,000 
      yoy
    		-78.22% -98.51% -65.79% -74.47% -47.47% 54.56% -24.53% -27.50% -27.20% -29.77% -26.53% -38.98% -81.73% -45.04% -53.39% -17.05% 178.44% 37.03% 73.26% -3.55% 7.84% 102.35% 6128.49% 148.84% 1010.56% -4252.04% -74.38%     
      qoq
    		392.00% -90.55% 30.75% -64.17% -66.23% 116.28% -2.43% -26.29% -0.64% 5.60% -6.26% -25.99% -4.14% 10.47% -22.14% -77.83% 188.29% -6.32% 38.56% -25.60% 41.88% 18.45% -22.87% -16.81% 166.22% 3546.06% -96.92% 271.29% -1095.31% -122.50%  
      operating margin %
    		-7.33% -1.03% -12.03% -9.72% -27.60% -72.23% -40.23% -45.09% -63.62% -64.21% -79.93% -80.86% -99.35% -116.63% -98.29% -122.59% -1119.84% -229.42% -319.49% -296.57% -292.69% -302.25% -304.02% -482.23% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% Infinity% -Infinity% 
      other income
    		                    -2,168,000 318,000 -8,000 794,000        
      interest income
    		-30,394,000 11,742,000 8,997,000 9,665,000 11,863,000 12,460,000 13,451,000 14,245,000 14,214,000 13,375,000 12,471,000 11,180,000 9,507,000 7,209,000 3,775,000 2,046,000 1,671,500 2,064,000 2,293,000 2,329,000 3,149,000 3,781,000 3,734,000 7,751,000 11,703,000 12,531,000 2,720,000 107,000  -37,000  
      share of income from equity method investments
    		      917,000 1,448,000 752,000 1,057,000 270,000 -496,000 -964,000 -1,119,000 5,197,000                 
      gain on revaluation of loan receivable
    		     11,804,000                          
      gain on revaluation of equity method investment
    		     32,469,000                          
      gain on revaluation of financial instruments
    		868,750 4,066,000  49,000   -3,615,000  -4,186,000 -5,291,000 5,193,000 -7,758,000 -4,466,000 17,049,000 -2,112,000 4,268,000                
      impairment loss on other investments
    		      -12,916,000 -12,734,000     -21,182,000 -28,972,000  -11,238,000                
      foreign currency gain
    		-4,542,500 19,785,000 -39,538,000                             
      loss on held-for-sale assets
    		-1,383,000 -3,031,000 -2,501,000  -780,000 -10,422,000                          
      change in allowance for credit loss on non-operating loan
    		-1,192,750 -4,771,000                              
      other
    		123,000 -283,000 -1,000 43,000 387,000 -315,000 248,000 -652,000 89,000 966,000 -26,000 85,000 63,000 -693,000 2,000 135,000 296,000 273,000 1,127,000             
      total other income
    		1,291,250 27,508,000 -33,683,000 11,340,000 57,310,000 38,271,000 4,628,000 12,906,000 -23,875,000 18,931,000 14,777,000 1,303,000 -17,135,000 -3,764,000 7,420,000 3,758,000 33,747,000 133,839,000 117,553,000 -118,145,000 -52,812,000 111,094,000 -72,948,000 120,741,000 838,199,000 270,978,000 430,808,000 -608,000 -42,000 -34,000 240,000 
      income before income taxes
    		620,000 27,005,000 -39,007,000 7,268,000 45,945,000 4,616,000 -10,933,000 -3,042,000 -45,511,000 -2,844,000 -5,843,000 -20,693,000 -46,854,000 -34,768,000 -20,646,000 -32,291,000 -65,742,750 77,425,000   -111,222,000 69,925,000 -107,703,000 75,681,000 784,037,000 250,633,000 430,250,000 -18,716,000 -4,919,000 456,000 -1,938,000 
      income tax benefit
    		-574,000 -1,316,000 -525,000 -455,000 -1,360,000 -2,708,000 -2,174,000 -558,000    -1,436,000 543,000 2,118,000 -308,000                 
      net income
    		-609,500 28,321,000 -38,482,000 7,723,000 43,941,000 7,324,000 -8,759,000 -2,484,000 -45,027,000 -1,772,000 -8,497,000 -19,257,000 -78,857,000 -36,886,000 -20,338,000 -32,653,000 -133,892,000 77,666,000 56,775,000 -161,625,000 -111,712,000 68,464,000 -107,703,000 75,681,000 787,996,000 250,968,000 427,693,000 -19,205,000 -7,271,000 723,000 -1,050,000 
      yoy
    		-101.39% 286.69% 339.34% -410.91% -197.59% -513.32% 3.08% -87.10% -42.90% -95.20% -58.22% -41.03% -41.10% -147.49% -135.82% -79.80% 19.85% 13.44% -152.71% -313.56% -114.18% -72.72% -125.18% -494.07% -10937.52% 34612.03% -40832.67%     
      qoq
    		-102.15% -173.60% -598.28% -82.42% 499.96% -183.62% 252.62% -94.48% 2441.03% -79.15% -55.88% -75.58% 113.79% 81.36% -37.71% -75.61% -272.39% 36.80% -135.13% 44.68% -263.17% -163.57% -242.31% -90.40% 213.98% -41.32% -2326.99% 164.13% -1105.67% -168.86%  
      net income margin %
    		-1.81% 58.00% -86.96% 18.43% 106.70% 15.72% -22.65% -7.02% -132.41% -5.23% -32.94% -70.79% -263.63% -138.75% -71.23% -111.04% -921.93% 315.84% 301.23% -1102.94% -559.79% 502.64% -942.12% 809.94% Infinity% Infinity% Infinity% -Infinity% -Infinity% Infinity% -Infinity% 
      net income attributable to non-controlling interest
    		1,298,250 2,363,000 1,229,000 1,601,000     -88,250 -128,000  -88,000 -6,750 105,000 -117,000 -15,000   -279,000             
      net income attributable to cronos group
    		-1,907,750 25,958,000 -39,711,000 6,122,000 43,729,000 8,349,000      -19,169,000 -22,462,500 -36,991,000 -20,221,000 -32,638,000 -133,637,000 77,916,000 57,054,000             
      comprehensive income
    		7,175,750 2,316,000 21,746,000 4,641,000 -22,267,000 19,732,000 -18,919,000    8,083,000  -39,658,250 -97,458,000   -64,094,000 54,848,000 70,245,000  197,000 94,631,000 -55,832,000 -38,011,000 786,941,000 250,864,000 427,812,000 -19,155,000 -7,035,000 762,000  
      other comprehensive income
    		                               
      foreign exchange gain on translation
    		7,785,250 -26,005,000 60,228,000  -66,208,000 12,408,000 -10,160,000 -22,361,000   16,580,000 2,414,000 18,140,000 -60,572,000 -24,161,000 15,977,000 1,734,000 -22,818,000 13,470,000 16,284,000 -8,913,500 26,167,000 51,871,000 -113,692,000        
      comprehensive income attributable to non-controlling interests
    		1,621,000 1,629,000 3,412,000 1,443,000   58,000  -34,000 -41,000 -87,000  15,500 201,000 122,000 -261,000                
      comprehensive income attributable to cronos group
    		5,554,750 687,000 18,334,000 3,198,000 -19,435,000 20,001,000 -18,977,000    8,170,000  -39,673,750 -97,659,000   -64,135,750 55,113,000 70,639,000             
      net income per share
    		                               
      basic net income per share attributable to cronos group
    		-0.005 0.07 -0.1 0.02 0.12 0.02                          
      diluted net income per share attributable to cronos group
    		-0.005 0.07 -0.1 0.02 0.12 0.02                          
      loss on revaluation of financial instruments
    		  -640,000  -1,637,500 -293,000  -2,642,000                        
      foreign currency transaction gain
    		   1,583,000 45,489,000 -7,432,000 6,543,000 13,259,000 999,750 8,816,000   -584,250 2,387,000                  
      foreign exchange loss on translation
    		   -3,082,000     -274,000 -20,090,000                      
      balance as of december 31, 2024
    		   382,530,780                            
      activities relating to share-based compensation
    		   2,875,615   712,325  11,763,019 240,518 240,518                     
      balance as of march 31, 2025
    		   385,406,395                            
      income from continuing operations
    		    43,941,000 7,324,000       -22,469,250 -36,886,000 -20,338,000 -32,653,000 -65,703,000 77,584,000 57,336,000 -161,604,000 -111,581,000 68,937,000          
      loss from discontinued operations
    		        124,000 -182,000 -2,834,000                     
      net loss attributable to non-controlling interest
    		    -317,500 -1,025,000 -2,000 -243,000   -137,000      -210,500 -250,000              
      comprehensive loss attributable to non-controlling interests
    		    -86,000 -269,000  -133,000    -8,000                    
      basic - continuing operations
    		    0.12 0.02      -0.05 -0.06 -0.1 -0.05 -0.09 -0.178 0.21  -0.44 0.028 0.2          
      basic - discontinued operations
    		                               
      diluted - continuing operations
    		    0.12 0.02      -0.05 -0.06 -0.1 -0.05 -0.09 -0.178 0.21  -0.44 0.025 0.19          
      diluted - discontinued operations
    		                               
      loss from continuing operations
    		      -8,759,000 -2,484,000 -45,151,000 -1,590,000 -5,663,000                     
      net loss attributable to cronos group
    		      -8,757,000 -2,241,000 -44,790,000 -1,644,000 -8,360,000                     
      basic and diluted - continuing operations
    		      -0.02 -0.01 -0.11  -0.01        0.15             
      basic and diluted - discontinued operations
    		          -0.01                     
      basic and diluted - total
    		      -0.02 -0.01 -0.11                       
      balance as of january 1, 2024
    		      381,298,853                         
      balance as of march 31, 2024
    		      382,011,178                         
      balance as of june 30, 2024
    		      382,280,725                         
      loss on revaluation of derivative liabilities
    		       -18,000                        
      comprehensive loss
    		       -24,845,000 -22,392,000 -21,862,000  -16,843,000   -44,499,000 -16,676,000    -145,341,000           -1,085,000 
      comprehensive loss attributable to cronos group
    		       -24,712,000 -22,002,000 -21,821,000  -16,835,000   -44,621,000 -16,415,000                
      number of shares
    		                               
      gain on revaluation of derivative liabilities
    		        -71,000 8,000 43,000 -65,000 -144,000 375,000 3,410,000 10,419,000 32,822,500 132,916,000 115,248,000 -116,874,000 -53,541,000 105,307,000 -35,880,000 113,368,000 835,079,000 263,943,000 436,383,000     
      income tax expense
    		        -360,000 -1,254,000 -180,000     362,000 -39,750 -159,000   359,000 988,000      489,000 2,352,000  -888,000 
      balance as of january 1, 2023
    		        10,670.5 380,575,403 380,575,403                     
      balance as of march 31, 2023
    		        11,011 380,815,921 380,815,921                     
      balance as of june 30, 2023
    		        11,329.25 381,089,357 381,089,357                     
      balance as of september 30, 2023
    		        11,783.25 381,113,564                      
      foreign currency transaction loss
    		          -3,174,000 -1,643,000   -2,852,000 -1,872,000                
      basic and diluted - discontinued operations
    		          -0.01                     
      basic and diluted
    		          -0.02                     
      net income from continuing operations per share
    		                               
      impairment loss on goodwill and indefinite-lived intangible assets
    		                1,000,000 142,000              
      income from discontinued operations
    		                 82,000 -561,000 -21,000 -131,000 -473,000          
      share of income from equity accounted investments
    		                  -1,115,000             
      share-based payments
    		                2,420,000 2,667,000 2,565,000 2,499,000 2,463,000 7,916,000 2,546,000 2,436,000 3,125,000 2,002,000 737,000 4,238,000 1,223,000 950,000  
      share of loss from equity accounted investments
    		                -1,043,000 -1,414,000              
      gain on disposal of other investments
    		                    46,000 3,974,000          
      other comprehensive income:
    		                               
      total other comprehensive income
    		                1,734,000 -22,818,000 13,470,000 16,284,000 -8,913,500 26,167,000 51,871,000 -113,692,000 -1,055,000 -104,000 119,000 50,000 236,000   
      less: comprehensive income attributable to non-controlling interests
    		                41,750 -265,000 -394,000             
      balance at july 1, 2021
    		                8,092 371,805,547              
      vesting of options
    		                471.5               
      options exercised
    		                -2.5 6,674     1,068,930         
      restricted share units settled
    		                -40.5 23,150              
      share issuance pursuant to research and development milestones
    		                 1,467,490              
      withholding taxes on share-based awards
    		                -7.75               
      vesting of restricted share units
    		                195.25               
      vesting of common shares issued in connection with the use of certain publicity rights in brand development
    		                85.75               
      accelerated restricted share units vesting out-of-period adjustment
    		                -1,200.5               
      balance at september 30, 2021
    		                7,593.25 373,302,861              
      gross loss
    		                  -15,784,000             
      weighted-average number of outstanding shares
    		                               
      basic
    		                  371,721,382 363,012,740 351,576,848 350,288,783 349,075,408 348,817,472 338,957,949 334,665,873 218,949,590 172,269,170 177,483,122 175,529,196  
      diluted
    		                  375,349,856 363,012,740 351,576,848 369,619,020 349,075,408 375,574,354 369,268,672 374,676,595 271,086,575 172,269,170 177,483,122 211,524,230  
      impairment loss on property, plant and equipment and right-of-use assets
    		                   -1,741,000            
      other loss
    		                   -1,859,000            
      net income attributable to:
    		                               
      cronos group
    		                   -161,312,000 -111,233,000 69,033,000 -106,977,000 76,040,000 788,368,000 251,117,000 427,829,000 -18,970,000 -7,210,000   
      non-controlling interests
    		                   -313,000 -479,000 -569,000 -726,000 -359,000 -372,000 -149,000 -136,000 -235,000 -61,000   
      comprehensive income attributable to:
    		                               
      share of income from investments in equity accounted investees
    		                    -1,217,000 -1,327,000    -991,000 -264,000 -936,000    
      financing and transaction costs
    		                     -40,000   -8,031,000 -4,505,000      
      impairment loss on goodwill and intangible assets
    		                      -40,000,000         
      loss on reclassification of held-for-sale assets
    		                    -229,750 -919,000          
      share of loss from investments in equity accounted investees
    		                      -794,000 -1,172,000        
      net income per share
    		                               
      basic
    		                      -0.31 0.22    -0.11    
      diluted
    		                      -0.31 0.2    -0.11    
      balance at march 31, 2020
    		                      348,817,472         
      top-up rights exercised
    		                               
      balance at june 30, 2020
    		                      349,886,402         
      balance at march 31, 2019
    		                      333,020,377         
      share issuance costs
    		                               
      warrants exercised
    		                      3,000,000         
      other comprehensive loss
    		                               
      balance at june 30, 2019
    		                      336,144,543         
      income tax recovery
    		                             -267,000  
      balance as of january 1, 2020
    		                       348,817,472        
      balance as of march 31, 2020
    		                       348,817,472        
      gross revenue
    		                        13,339,000 10,787,000 6,985,000 17,145,000    
      cost of sales before fair value adjustments
    		                        7,432,000 4,762,000 2,984,000 7,654,000 1,688,000   
      gross profit before fair value adjustments
    		                        5,268,000 5,475,000 3,486,000 8,049,000 2,072,000 2,140,000  
      fair value adjustments
    		                               
      unrealized change in fair value of biological assets
    		                        10,015,000 -4,024,000 -13,553,000 -11,568,000 -1,533,000 -6,831,000  
      realized fair value adjustments on inventory sold in the period
    		                        14,617,000 3,557,000 3,722,000  1,511,000 2,625,000  
      total fair value adjustments
    		                        24,632,000 -467,000 -9,831,000 -3,219,000 -22,000 -4,206,000  
      gain on revaluation of financial liabilities
    		                        194,000       
      share of income from equity accounted investees
    		                        -746,000       
      gain on disposal of whistler
    		                          20,606,000     
      gain on other investments
    		                          924,000 221,000   221,000 
      deferred income tax (recovery) expense
    		                        -3,959,000 -335,000      
      net income attributable to: - sum
    		                        787,996,000 250,968,000 427,693,000 -19,205,000    
      gain on revaluation or disposal of other investments
    		                        -300,000       
      foreign exchange gain on translation of subsidiaries
    		                        -755,000       
      earnings per share
    		                               
      basic
    		                        2.33 0.75 1.95     
      diluted
    		                        0.53 0.22 0.48     
      the accompanying notes are an integral part of these unaudited condensed interim consolidated financial statements
    		                               
      gain on revaluation and disposal of other investments, net of tax
    		                          103,000 46,000 233,000 39,000  
      foreign exchange loss on translation of foreign operations
    		                         -104,000      
      comprehensive income attributable to: - sum
    		                         250,864,000 427,812,000 -19,155,000    
      financing costs
    		                          -29,561,000     
      deferred income tax expense
    		                          2,557,000     
      foreign exchange gain on translation of foreign operations
    		                          16,000 4,000 3,000   
      realized fair value adjustments on inventory sold in the year
    		                           8,349,000    
      unrealized gains reclassified to net income
    		                               
      revenue
    		                            3,760,000 3,394,000  
      interest expense
    		                            -62,000  -22,000 
      share of income from investment in associate
    		                            20,000   
      net income per share
    		                               
      basic and diluted
    		                            -0.04  -0.01 
      inventory expensed to cost of sales, before fair value adjustments
    		                             1,254,000  
      share of income from whistler investment
    		                             3,000 41,000 
      product sales
    		                              2,945,000 
      inventory expensed to cost of sales
    		                              3,761,000 
      production costs
    		                              1,714,000 
      unrealized gain on revaluation of biological assets
    		                              -4,458,000 
      total cost of sales
    		                              1,017,000 
      general and administration
    		                              2,461,000 
      stock-based payments
    		                              774,000 
      gain on revaluation of other investments, net of tax
    		                              -35,000 
      weighted-average number of outstanding shares
    		                               
      basic and diluted
    		                              157,054,891 
    Balance Sheets:
    Quarterly
    Annual
      Unit: USD2026-03-31 2025-12-31 2025-09-30 2025-06-30 2025-03-31 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-11-12 2019-09-30 2019-08-08 2019-06-30 2019-05-09 2019-03-31 2019-03-26 2018-11-13 2018-09-30 2018-08-14 
                                         
        assets
      		                                   
        current assets
      		                                   
        cash and cash equivalents
      		821,856,000 791,794,000 784,170,000 794,416,000 797,819,000 858,805,000 862,034,000 848,189,000 855,114,000 669,291,000 571,656,000 409,428,000 413,667,000 764,644,000 633,296,000 789,543,000 861,535,000 886,973,000 842,567,000 895,181,000 1,024,450,000 1,078,023,000 1,097,846,000 1,109,700,000 1,128,396,000 1,475,459,000 1,475,459,000 1,579,231,000 1,579,231,000 2,418,277,000 2,418,277,000     
        short-term investments
      		 40,000,000 40,000,000 40,000,000 40,000,000     192,237,000 267,905,000 431,510,000 422,763,000 113,077,000 255,452,000 155,352,000 119,933,000 117,684,000 197,161,000 201,699,000 214,925,000 211,766,000 202,883,000 213,614,000 206,230,000 517,064,000 517,064,000 744,936,000 744,936,000       
        accounts receivable
      		32,962,000 34,099,000 27,091,000 26,619,000 18,714,000 15,462,000 20,480,000 16,179,000 15,336,000 13,984,000 15,730,000 12,540,000 14,855,000 23,113,000 19,092,000 19,375,000 25,814,000 22,067,000 14,669,000 11,299,000 6,997,000 8,928,000 6,086,000 3,477,000 3,404,000 12,655,000 12,655,000 11,960,000 11,960,000 5,559,000 5,559,000 4,163,000 3,278,000 3,278,000 2,844,000 
        interest receivable
      		5,734,000 8,654,000 6,548,000 3,228,000 4,952,000 8,690,000 7,190,000 5,183,000 3,864,000 10,012,000 11,723,000 9,452,000              3,829,000 3,829,000 5,751,000 5,751,000 3,130,000 3,130,000     
        other receivables
      		13,546,000 14,445,000 4,357,000 9,529,000 7,354,000 5,000,000 5,690,000 7,227,000 5,919,000 6,341,000 4,707,000 4,839,000 7,049,000 5,767,000 3,742,000 2,175,000 3,297,000 5,765,000 1,723,000 2,468,000 3,796,000 10,033,000 10,401,000 9,568,000 7,642,000           
        current portion of loans receivable
      		128,000  176,000  737,000 618,000 233,000 4,875,000 5,668,000 5,541,000 5,157,000 5,035,000 5,570,000 8,890,000 8,739,000 7,613,000 6,235,000 5,460,000 5,779,000 5,028,000 6,717,000 7,083,000 7,781,000 4,458,000 3,911,000 6,083,000 6,083,000         
        inventory
      		48,676,000 46,750,000 48,167,000 42,142,000 34,603,000 33,149,000 47,250,000 29,182,000 30,639,000 30,495,000 35,847,000 45,190,000 44,268,000 37,559,000 34,094,000 39,842,000 37,054,000 32,802,000 31,769,000 35,605,000 46,437,000 44,002,000 56,359,000 53,216,000 43,118,000 52,865,000 52,865,000 41,667,000 41,667,000 25,150,000 25,150,000 11,584,000 15,073,000 15,073,000 12,334,000 
        prepaids and other current assets
      		4,974,000 8,344,000 8,769,000 5,191,000 6,313,000 6,277,000 7,326,000 5,246,000 6,278,000 5,405,000 5,656,000 6,780,000 7,967,000 7,106,000 8,896,000 12,150,000 9,537,000 8,967,000 10,196,000 10,153,000 15,053,000               
        total current assets
      		927,876,000 944,086,000 922,151,000 927,147,000 918,581,000 936,113,000 959,174,000 935,278,000 942,216,000 933,306,000 918,381,000 924,774,000 916,139,000 960,156,000 963,311,000 1,026,050,000 1,063,405,000 1,079,718,000 1,103,864,000 1,162,078,000 1,320,344,000 1,372,172,000 1,393,954,000 1,401,860,000 1,403,780,000 2,086,422,000 2,086,422,000 2,408,592,000 2,408,592,000 2,474,308,000 2,474,308,000 65,064,000 85,978,000 85,978,000 123,064,000 
        other investments
      		5,199,000 7,664,000 11,443,000 2,251,000 2,755,000 2,813,000 2,900,000 3,168,000 19,758,000 35,251,000 62,143,000 67,925,000 62,833,000 70,993,000 94,557,000 108,669,000 111,761,000 118,392,000 110,392,000 110,392,000        300,000 300,000 300,000 300,000 705,000 994,000 994,000 725,000 
        non-current portion of loans receivable
      		20,803,000 20,847,000 22,409,000 13,767,000 15,587,000 15,526,000 16,086,000 73,165,000 66,545,000 69,036,000 68,301,000 71,080,000 72,051,000 72,345,000 72,064,000 78,436,000 81,529,000 80,635,000                  
        property, plant and equipment
      		142,102,000 145,865,000 145,536,000 150,243,000 139,185,000 133,189,000 162,516,000 36,964,000 37,171,000 59,468,000 55,604,000 57,695,000 59,785,000 60,557,000 60,582,000 66,316,000 71,828,000 74,070,000 188,644,000 193,920,000 192,123,000 187,599,000 171,404,000 164,290,000 154,164,000 216,277,000 216,277,000 196,718,000 196,718,000 184,570,000 184,570,000 171,891,000 127,595,000 127,595,000 93,657,000 
        right-of-use assets
      		1,303,000 1,422,000 1,529,000 1,677,000 1,320,000 1,390,000 1,052,000 1,079,000 1,213,000 1,356,000 1,417,000 1,571,000 2,038,000 2,273,000 5,103,000 6,113,000 6,325,000 8,882,000 9,386,000 6,687,000 8,538,000 9,776,000 9,840,000 10,100,000 10,379,000 7,957,000 7,957,000 3,359,000 3,359,000 1,875,000 1,875,000     
        goodwill
      		65,436,000 66,478,000 65,413,000 66,918,000 63,268,000 63,453,000 38,028,000 1,024,000 1,035,000 1,057,000 1,031,000 1,057,000 1,036,000 1,033,000 1,012,000 1,087,000 1,119,000 1,098,000 1,104,000 179,543,000 179,531,000 179,522,000 179,459,000 179,736,000 214,689,000 284,227,000 284,227,000 1,792,000 1,792,000 1,792,000 1,792,000 1,792,000 1,792,000 1,792,000 1,792,000 
        intangible assets
      		8,549,000 8,890,000 9,829,000 10,565,000 10,625,000 11,257,000 4,247,000 19,103,000 20,018,000 21,078,000 24,236,000 25,462,000 25,897,000 26,704,000 21,428,000 23,722,000 17,880,000 18,079,000 20,471,000 70,409,000 70,085,000 69,720,000 68,604,000 69,399,000 72,599,000 96,047,000 96,047,000 11,461,000 11,461,000 11,087,000 11,087,000 11,234,000 11,345,000 11,345,000 11,043,000 
        deferred tax assets
      		841,000 1,888,000 100,000 2,659,000 2,506,000 2,571,000                              
        total assets
      		1,172,109,000 1,197,140,000 1,178,410,000 1,175,227,000 1,153,827,000 1,166,312,000 1,184,133,000 1,091,048,000 1,108,535,000 1,140,085,000 1,150,112,000 1,168,347,000 1,159,575,000 1,213,009,000 1,237,459,000 1,332,213,000 1,371,001,000 1,397,738,000 1,535,199,000 1,838,611,000 1,881,282,000 1,925,682,000 1,918,929,000 1,910,287,000 1,927,926,000 2,762,768,000 2,762,768,000 2,667,519,000 2,667,519,000 2,698,037,000 2,698,037,000 261,119,000 234,450,000 234,450,000 235,436,000 
        liabilities
      		                                   
        current liabilities
      		                                   
        accounts payable
      		10,281,000 11,640,000 10,865,000 12,136,000 9,499,000 16,973,000 6,532,000 7,840,000 9,401,000 12,130,000 4,749,000 9,340,000 12,842,000 11,163,000 9,989,000 12,449,000 10,904,000 11,218,000                  
        income taxes payable
      		1,369,000  1,000 14,000 12,000 9,000 94,000 61,000 73,000 64,000 635,000 438,000 266,000 32,956,000                      
        accrued liabilities
      		30,601,000 36,210,000 29,625,000 24,637,000 22,547,000 31,653,000 31,766,000 23,846,000 22,503,000 27,736,000 23,868,000 16,573,000 14,332,000 22,268,000 25,629,000 23,905,000 23,076,000 26,069,000                  
        current portion of lease obligation
      		169,000 337,000 576,000 822,000 977,000 1,025,000 980,000 931,000 958,000 994,000 949,000 1,174,000 1,236,000 1,330,000 1,900,000 2,267,000 2,173,000 2,711,000 2,959,000 1,206,000 1,130,000 1,322,000 1,274,000 1,206,000 1,057,000           
        total current liabilities
      		42,420,000 48,187,000 41,067,000 37,612,000 33,048,000 49,700,000 39,564,000 33,057,000 33,419,000 41,399,000 30,584,000 27,926,000 29,131,000 68,116,000 37,970,000 39,195,000 40,252,000 54,373,000 69,602,000 200,598,000 302,643,000 206,834,000 142,941,000 235,236,000 201,523,000 604,394,000 604,394,000 1,433,662,000 1,433,662,000 1,719,642,000 1,719,642,000 45,493,000 9,529,000 9,529,000 2,333,000 
        non-current portion due to non-controlling interests
      		749,000 733,000 698,000 680,000 611,000 1,073,000 1,243,000 1,137,000 1,033,000 1,003,000 1,009,000 1,023,000 1,370,000 1,383,000 1,346,000                     
        non-current portion of lease obligation
      		1,142,000 1,172,000 1,166,000 1,189,000 840,000 993,000 872,000 1,062,000 1,305,000 1,559,000 1,754,000 2,050,000 2,296,000 2,546,000 4,994,000 6,653,000 7,094,000 7,095,000                  
        deferred tax liabilities
      		3,984,000 4,089,000 3,430,000 5,540,000 4,563,000 3,564,000                              
        total liabilities
      		48,295,000 54,181,000 46,361,000 45,021,000 39,062,000 55,330,000 52,822,000 35,256,000 35,757,000 43,961,000 33,347,000 31,674,000 33,175,000 72,045,000 46,227,000 47,250,000 49,630,000 63,462,000 78,774,000 208,699,000 313,003,000 217,514,000 154,442,000 247,242,000 212,658,000 614,593,000 614,593,000 1,443,056,000 1,443,056,000 1,728,087,000 1,728,087,000 49,479,000 12,185,000 12,185,000 8,166,000 
        shareholders’ equity
      		                                   
        share capital and additional paid-in capital
      		647,040,000 662,983,000 666,147,000 666,614,000 669,036,000 669,879,000                              
        retained earnings
      		460,540,000 447,756,000 450,032,000 424,080,000 463,816,000 457,709,000 413,995,000 405,650,000 414,478,000 416,719,000 461,509,000 463,153,000 471,513,000 490,682,000 569,566,000 606,557,000 626,778,000 659,416,000 793,277,000 955,721,000 895,503,000 1,064,509,000 1,175,742,000 1,106,709,000 1,213,686,000 1,443,382,000 1,443,382,000 655,047,000 655,047,000 404,499,000 404,499,000     
        accumulated other comprehensive loss
      		-33,918,000 -16,842,000 -33,675,000 -8,404,000 -66,449,000      -2,110,000                         
        total equity attributable to shareholders of cronos group
      		1,073,662,000 1,093,897,000 1,082,504,000 1,082,290,000 1,066,403,000 1,064,063,000 1,081,560,000 1,059,314,000 1,076,358,000 1,099,571,000 1,119,822,000 1,139,689,000 1,129,329,000 1,143,885,000 1,194,137,000 1,288,069,000 1,324,599,000 1,337,243,000 1,459,454,000 1,632,676,000 1,570,649,000 1,711,364,000 1,766,990,000 1,664,996,000 1,716,457,000 2,148,712,000 2,148,712,000 1,224,614,000 1,224,614,000 969,954,000 969,954,000 211,504,000    
        non-controlling interests
      		50,152,000 49,062,000 49,545,000 47,916,000 48,362,000 46,919,000 49,751,000 -3,522,000 -3,580,000 -3,447,000 -3,057,000 -3,016,000 -2,929,000 -2,921,000 -2,905,000 -3,106,000 -3,228,000 -2,967,000 -3,029,000 -2,764,000 -2,370,000 -3,196,000 -2,503,000 -1,951,000 -1,189,000 -537,000 -537,000 -151,000 -151,000 -4,000 -4,000 136,000 311,000 311,000  
        total shareholders’ equity
      		1,123,814,000 1,142,959,000 1,132,049,000 1,130,206,000 1,114,765,000 1,110,982,000 1,131,311,000 1,055,792,000 1,072,778,000 1,096,124,000 1,116,765,000 1,136,673,000 1,126,400,000 1,140,964,000 1,191,232,000 1,284,963,000 1,321,371,000 1,334,276,000 1,456,425,000 1,629,912,000 1,568,279,000  1,764,487,000 1,663,045,000 1,715,268,000           
        total liabilities and shareholders’ equity
      		1,172,109,000 1,197,140,000 1,178,410,000 1,175,227,000 1,153,827,000 1,166,312,000 1,184,133,000 1,091,048,000 1,108,535,000 1,140,085,000 1,150,112,000 1,168,347,000 1,159,575,000 1,213,009,000 1,237,459,000 1,332,213,000 1,371,001,000 1,397,738,000 1,535,199,000 1,838,611,000 1,881,282,000 1,925,682,000 1,918,929,000 1,910,287,000 1,927,926,000           
        held-for-sale assets
      		  2,873,000 6,022,000 8,089,000 8,112,000 8,971,000 19,197,000 19,398,000           645,000 1,969,000 1,176,000 2,066,000             
        derivative liabilities
      		   3,000 13,000 40,000 192,000 21,000 118,000 102,000 29,000 37,000 80,000 15,000 73,000 574,000 4,099,000 14,375,000 34,528,000 169,563,000 272,300,000 163,410,000 102,655,000 205,714,000 166,176,000 545,514,000 545,514,000 1,399,594,000 1,399,594,000 1,664,275,000 1,664,275,000     
        equity method investments
      		       21,226,000 20,521,000 19,488,000 18,258,000 17,646,000 18,313,000 18,755,000 19,234,000 21,731,000                    
        current portion due to non-controlling interests
      		       358,000 366,000 373,000 354,000 364,000 375,000 384,000 379,000                     
        accumulated other comprehensive income
      		     -63,525,000    20,678,000  18,067,000 1,537,000 -797,000 -18,980,000 41,688,000 66,088,000 49,865,000 48,926,000 71,729,000 58,144,000 42,999,000 -7,820,000 -33,970,000 -85,877,000 -98,000 -98,000 944,000 944,000 1,049,000 1,049,000 930,000 1,119,000 1,119,000 884,000 
        other assets
      		      130,000 41,000 58,000        70,000 100,000 780,000                 
        deferred tax liability
      		      11,143,000     675,000                        
        share capital
      		      616,403,000 616,379,000 615,625,000 613,725,000 613,290,000 613,152,000 612,235,000 611,318,000 605,229,000 604,626,000 596,368,000 595,497,000 586,878,000 572,858,000 584,912,000 569,260,000 566,577,000 565,211,000 563,165,000 693,620,000 693,620,000 559,296,000 559,296,000 556,930,000 556,930,000 225,500,000 225,549,000 225,549,000 224,742,000 
        additional paid-in capital
      		      51,523,000 49,298,000 48,048,000 48,449,000 47,133,000 45,317,000 44,044,000 42,682,000 38,322,000 35,198,000 35,365,000 32,465,000 30,373,000 32,368,000 32,090,000 34,596,000 32,491,000 27,046,000 25,483,000           
        accumulated other comprehensive gain
      		      -361,000 -12,013,000 -1,793,000                           
        other
      		         45,000   1,483,000 193,000 168,000 89,000                    
        deferred tax asset
      		          741,000 1,137,000                        
        deferred income tax liability
      		            378,000  1,917,000 46,000 396,000 81,000        77,000 77,000 4,036,000 4,036,000 4,371,000 4,371,000 1,850,000 2,656,000 2,656,000 268,000 
        due to non-controlling interests
      		               1,356,000 1,888,000 1,913,000 1,829,000 1,768,000 2,129,000 2,188,000 2,889,000 3,048,000 1,681,000 2,378,000 2,378,000 2,249,000 2,249,000 2,247,000 2,247,000 2,136,000    
        investments in equity accounted investees
      		                17,084,000 16,764,000 19,094,000 20,970,000 19,221,000 19,235,000 19,059,000 933,000 1,089,000       3,492,000 4,072,000 4,072,000  
        loan receivable
      		                  81,464,000 94,113,000 90,953,000  76,148,000 65,371,000 54,147,000       314,000 314,000 314,000 314,000 
        accounts payable and other liabilities
      		                  32,115,000 29,829,000 29,213,000 42,102,000 39,012,000 28,316,000 34,290,000 57,722,000 57,722,000 30,747,000 30,747,000 45,016,000 45,016,000 15,532,000 3,066,000 3,066,000 2,333,000 
        lease obligation
      		                  7,343,000 6,333,000 8,231,000 8,492,000 8,612,000 8,958,000 9,454,000           
        commitments and contingencies
      		                                   
        advances to joint ventures
      		                   499,000 487,000 467,000 461,000 18,598,000 17,079,000 26,367,000 26,367,000 26,608,000 26,608,000 21,920,000 21,920,000 6,941,000    
        prepaids and other assets
      		                     11,161,000 10,532,000 7,827,000 11,079,000           
        loans receivable
      		                     87,191,000    44,082,000 44,082,000 16,664,000 16,664,000       
        total shareholders' equity
      		                     1,708,168,000    2,148,175,000 2,148,175,000 1,224,463,000 1,224,463,000 969,950,000 969,950,000 211,640,000 222,265,000 222,265,000 227,270,000 
        sales taxes receivable
      		                         4,624,000 4,624,000 7,936,000 7,936,000 5,594,000 5,594,000 3,419,000 9,953,000 9,953,000 6,952,000 
        prepaid expenses and other assets
      		                         11,742,000 11,742,000 7,079,000 7,079,000 5,092,000 5,092,000     
        biological assets
      		                         2,101,000 2,101,000 10,032,000 10,032,000 11,506,000 11,506,000 9,074,000 5,632,000 5,632,000 6,899,000 
        net investments in equity accounted investees
      		                         1,389,000 1,389,000 2,025,000 2,025,000 2,185,000 2,185,000     
        holdbacks payable
      		                           2,274,000 2,274,000 8,482,000 8,482,000 7,887,000    
        government remittances payable
      		                         738,000 738,000 630,000 630,000 1,313,000 1,313,000 1,123,000 739,000 739,000  
        current portion of lease obligations
      		                         420,000 420,000 417,000 417,000 134,000 134,000     
        construction loan payable
      		                               20,951,000 5,724,000 5,724,000 5,565,000 
        lease obligations
      		                         7,744,000 7,744,000 3,109,000 3,109,000 1,827,000 1,827,000     
        shareholders' equity
      		                                   
        share-based reserve
      		                         11,808,000 11,808,000         
        total liabilities and shareholders' equity
      		                         2,762,768,000 2,762,768,000 2,667,519,000 2,667,519,000 2,698,037,000 2,698,037,000 261,119,000 234,450,000 234,450,000 235,436,000 
        subsequent events
      		                                   
        the accompanying notes are an integral part of these unaudited condensed interim consolidated financial statements
      		                                   
        approved on behalf of the board of directors:
      		                                   
        "michael gorenstein"
      		                                   
        director
      		                                   
        warrants
      		                           754,000 754,000 845,000 845,000 1,548,000 1,548,000 1,548,000 1,868,000 
        stock options
      		                           8,573,000 8,573,000 6,631,000 6,631,000 6,241,000 4,982,000 4,982,000 3,810,000 
        bank indebtedness
      		                             422,000 422,000     
        cash
      		                               32,634,000 41,482,000 41,482,000 89,609,000 
        prepaids and other receivables
      		                               3,876,000 10,246,000 10,246,000 4,112,000 
        accumulated deficit
      		                               -22,715,000 -11,261,000 -11,261,000 -4,051,000 
        advances to related corporations
      		                                2,674,000 2,674,000  
        shares to be issued
      		                                17,000 17,000 17,000 
        total equity attributable to shareholders of cronos
      		                                221,954,000 221,954,000  
        promissory note receivable
      		                                  1,304,000 
        investment in whistler
      		                                  3,851,000 
      Cashflow Statements:
      Quarterly
      Annual
        Unit: USD2026-03-31 2025-12-31 2025-09-30 2025-06-30 2025-03-31 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-09-30 2019-06-30 2019-05-09 2019-03-31 2019-03-26 2018-09-30 2018-08-14 2018-05-15 2018-03-31 
                                          
          operating activities
        		                                  
          net income
        		15,711,000    7,723,000             -133,892,000   -161,625,000 -111,712,000 68,464,000 -107,703,000 75,681,000 537,028,000 -176,725,000 427,693,000 427,693,000 -19,205,000 -7,115,000   -1,050,000 
          adjustments to reconcile net income to net cash from operating activities:
        		                                  
          share-based compensation
        		1,313,000 1,248,000 2,333,000 1,381,000 2,088,000 2,187,000 2,262,000 2,236,000 2,015,000 1,929,000 1,953,000 2,336,000 2,551,000 4,548,000 4,265,000 2,616,000 3,686,000                  
          depreciation and amortization
        		3,727,000 3,657,000 3,532,000 4,202,000 2,840,000 2,525,000 3,567,000 1,513,000 1,731,000 1,177,000 2,148,000 2,380,000 2,405,000 2,623,000 3,448,000 4,227,000 2,824,000 6,491,000 3,828,000 3,203,000 1,880,000 1,950,000 2,216,000 1,717,000 1,162,000 232,000 205,000 470,000 470,000 1,256,000 70,000 35,000 540,000 540,000 
          loss from investments
        		2,484,000 3,928,000 -4,182,000 632,000 68,000 -262,000 371,000 2,838,000 894,000  4,148,000 -5,464,000 8,419,000 5,430,000 -16,090,000                    
          changes in expected credit losses on long-term financial assets
        		107,000 93,000 4,777,000 -20,000 9,000 6,000 5,000 1,212,000 -191,000 -189,000 -193,000 -382,000 -764,000 -85,000 78,000                    
          inventory step-up recorded to cost of sales
        		 0 0 0 517,000 -1,832,000                             
          foreign currency gain
        		-13,699,000                                  
          other non-cash operating activities
        		979,000 -1,117,000 1,038,000 550,000 779,000 -71,000 -840,000 -237,000 1,066,000 -90,000 2,094,000 -1,162,000 -2,850,000 -4,284,000 2,189,000 2,511,000 -4,467,000  -1,639,000 -2,941,000 1,749,000              
          changes in operating assets and liabilities:
        		                                  
          accounts receivable
        		879,000 -6,231,000 -716,000 -6,385,000 -3,409,000 4,485,000 -2,679,000 -1,069,000 -1,654,000 2,230,000 -3,647,000 2,422,000 8,201,000 -3,883,000 -809,000 5,511,000 -3,530,000 -7,416,000 -3,553,000 -4,125,000 1,931,000          -116,000    
          interest receivable
        		2,360,000 -2,106,000 -4,145,000 2,787,000 3,453,000 -2,638,000 -2,192,000 -3,077,000 4,251,000 257,000 -7,794,000                        
          other receivables
        		724,000 -9,942,000 5,012,000 -1,692,000 -2,379,000 401,000 2,667,000 -1,298,000 289,000 -1,474,000 225,000 1,082,000 -1,282,000 -2,549,000 -1,874,000 1,155,000 2,435,000 -3,593,000 471,000 1,273,000 5,687,000              
          prepaids and other current assets
        		3,310,000 546,000 -3,734,000 1,446,000 -60,000 705,000 -1,212,000 980,000 -985,000 363,000 594,000 1,328,000 -848,000 1,900,000 2,855,000 -2,564,000 -1,195,000 2,048,000 -214,000 5,005,000 -3,737,000              
          inventory
        		-2,039,000 2,630,000 -6,308,000 -5,086,000 -1,631,000 255,000 6,870,000 1,069,000 -777,000 6,423,000 8,235,000 -435,000 -6,824,000 -2,976,000 3,904,000 -4,278,000 -3,867,000 -2,770,000 15,345,000 -3,000 -1,007,000          1,695,000    
          accounts payable
        		-1,206,000 2,335,000 -171,000 581,000 -1,637,000 1,653,000 -4,620,000 -1,707,000 -2,775,000 6,822,000 -5,117,000 -4,033,000 1,555,000    -178,000                  
          income taxes payable
        		1,387,000 -1,000 -13,000 0 4,000 -84,000 38,000 -58,000 11,000 -376,000 73,000 12,000 -32,813,000                      
          accrued liabilities
        		-5,139,000 6,168,000 4,283,000 865,000 -8,878,000 1,207,000 4,949,000 1,746,000 -5,062,000 3,250,000 7,694,000 2,110,000 -7,894,000    -3,150,000                  
          net cash from operating activities
        		10,898,000 11,835,000 13,309,000 2,818,000 -2,096,000                              
          capital expenditures
        		-1,875,000 0 -4,483,000 -3,837,000 -15,258,000                              
          free cash flows
        		9,023,000 11,835,000 8,826,000 -1,019,000 -17,354,000                              
          investing activities
        		                                  
          purchase of short-term investments
        		 0 0 0 -40,000,000     -71,061,000 -57,423,000 -57,151,000 -422,612,000 3,992,000 -118,070,000   210,000 360,000    -986,000 1,938,000 -126,514,000          
          proceeds from short-term investments
        		40,000,000     -1,349,000 -281,000 -1,425,000 188,872,000 152,073,000 211,347,000 56,063,000 113,355,000 151,945,000 -1,050,000   79,502,000 -403,000                
          purchase of property, plant and equipment
        		-1,875,000      -6,415,000 -729,000 -1,724,000  11,000 -494,000 -804,000  -869,000 -1,507,000 -711,000  -2,304,000 -1,667,000 -6,680,000  -7,990,000 -6,933,000 -6,411,000 -7,610,000 -991,000 -13,454,000 -13,454,000 -114,407,000 -4,204,000 -22,383,000 -7,642,000 -7,642,000 
          purchase of intangible assets
        		-96,000      -121,000 -187,000 -270,000  -336,000    -756,000 -398,000 -23,000  -201,000 -451,000 -392,000 -885,000 -340,000 -1,649,000 -1,105,000 440,000 -526,000 -51,000 -51,000 -360,000 -87,000 93,000 -131,000 -131,000 
          net cash from investing activities
        		38,029,000 2,782,000 -23,002,000 -983,000 -55,356,000                              
          financing activities
        		                                  
          repurchases of common stock
        		-16,730,000 -4,270,000 -1,859,000                                
          withholding taxes paid on share-based awards
        		-1,538,000 -598,000 -7,000 -216,000 -2,930,000  -13,000 -260,000 -645,000  -30,000 -39,000 -743,000  -128,000 -1,546,000 -534,000  -4,263,000 -246,000 -8,673,000              
          net cash from financing activities
        		-18,268,000 -7,423,000 -1,866,000 -7,686,000 -2,930,000                              
          effect of foreign currency translation on cash and cash equivalents
        		-597,000 430,000 1,313,000 2,448,000 -604,000 -5,604,000 3,093,000 148,000 -884,000 -855,000 4,869,000 2,726,000 1,271,000 -2,118,000 -22,640,000 -12,721,000 8,837,000 -716,000 -13,203,000 7,403,000 11,422,000 36,887,000 20,631,000 39,621,000 -91,037,000          
          net change in cash and cash equivalents
        		30,062,000 7,624,000 -10,246,000 -3,403,000 -60,986,000 -3,229,000 13,845,000 -6,925,000 185,823,000 97,635,000 162,228,000 -4,239,000 -350,977,000 131,348,000 -156,247,000 -71,992,000 -25,438,000 44,406,000 -52,614,000 -129,269,000 -53,573,000     733,870,000 -3,224,211,000 2,385,720,000 2,385,720,000      
          cash and cash equivalents, beginning of period
        		791,794,000 0 0 0 858,805,000 0 0 0 669,291,000 0 0 0 764,644,000 0 0 0 886,973,000 0 0 0 1,078,023,000 0 0 0 1,199,693,000          
          cash and cash equivalents, end of period
        		821,856,000 7,624,000 -10,246,000 -3,403,000 797,819,000 -3,229,000 13,845,000 -6,925,000 855,114,000 97,635,000 162,228,000 -4,239,000 413,667,000 131,348,000 -156,247,000 -71,992,000 861,535,000 44,406,000 -52,614,000 -129,269,000 1,024,450,000 -19,823,000 -11,854,000 -18,696,000 1,128,396,000          
          supplemental cash flow information
        		                                  
          interest paid
        		                      66,000 83,000 7,000 0 -598,000 675,000 675,000 870,000 0 -118,000 307,000 307,000 
          interest received
        		9,370,000 6,982,000 7,697,000 11,399,000 13,052,000 9,434,000 10,674,000 13,650,000 14,641,000 14,298,000 8,818,000 5,827,000 7,558,000 7,814,000 4,244,000 2,668,000 822,000 4,963,000 1,064,000 1,804,000 1,157,000  1,898,000 3,817,000 7,758,000 -7,652,000         
          income taxes paid
        		8,000 36,000 9,000 9,000 50,000  7,000 35,000 579,000  18,000 63,000 32,932,000  18,000 74,000 66,000  15,000 234,000 624,000              
          impairment loss on goodwill and indefinite-lived intangible assets
        		                 1,000,000                 
          impairment loss on long-lived assets
        		 0    0 14,376,000 0 1,974,000 3,366,000 0   0 0 0 3,493,000 122,880,000 2,998,000                
          impairment loss on other investments
        		     0 0 12,916,000 12,734,000     21,182,000 28,972,000 0 11,238,000                  
          revaluation of equity method investment
        		     0                             
          revaluation of loan receivable
        		     0                             
          loss on held-for-sale assets
        		 0 3,031,000   780,000                             
          foreign currency loss
        		 10,418,000 -19,785,000                                
          purchase of other investments
        		 0                 0                
          proceeds from sale of held for sale assets
        		                                  
          cash acquired in business combination
        		                                  
          advances on loans receivable
        		 0    63,000 14,000            -1,841,000 -2,419,000 -2,645,000 -7,652,000 -13,026,000 -9,462,000 -14,512,000 -11,100,000         
          proceeds from repayment on loans receivable
        		 2,209,000 0    -8,000                            
          dividends received from equity method investment
        		          2,000                        
          dividend proceeds
        		         -1,000                         
          purchase of intangible assets, net of disposals
        		 -135,000 -105,000 -1,000 -98,000                              
          other investing activities
        		         -2,000    -2,000 0                    
          dividend paid to non-controlling interest
        		 -2,555,000 0                                
          supplementary cash flow information
        		                                  
          net loss
        		  28,321,000    7,324,000 -8,759,000 -2,484,000 -45,027,000 -1,772,000 -8,497,000 -19,257,000 -78,857,000 -36,886,000 -20,338,000 -32,653,000                -1,050,000  
          adjustments to reconcile net loss to net cash from operating activities:
        		                                  
          cash acquired in business combinations
        		                                  
          purchase of property, plant and equipment, net of disposals
        		  -4,483,000 -3,837,000 -15,258,000                              
          foreign currency transaction gain
        		    -1,583,000                              
          loss on revaluation of derivative liabilities
        		        18,000 71,000 -8,000 -43,000 65,000                      
          foreign currency transaction loss
        		       -6,543,000 -13,259,000 11,323,000 -8,816,000 3,174,000 1,643,000 -51,000 -2,387,000 2,852,000 1,872,000                  
          dividends received from equity method investee
        		                                  
          repayments on loans receivable
        		                                  
          withholding taxes paid on equity awards
        		                     0             
          other financing activities
        		             1,000 -115,000 -24,000 70,000                  
          taxes paid
        		                                  
          adjustments to reconcile net loss to cash from operating activities:
        		                                  
          cash flows from operating activities
        		      11,583,000 1,744,000 -2,204,000  -183,000 -11,774,000 -47,693,000  -13,385,000 -17,280,000 -33,911,000  -31,481,000 -40,195,000 -46,002,000  -27,491,000 -38,295,000 -38,898,000     -9,739,000 -5,772,000 6,884,000 -13,750,000  
          cash flows from investing activities
        		      -818,000 -8,557,000 189,556,000  157,572,000 4,848,000 -303,812,000  -119,979,000 -40,421,000 100,000  -3,673,000 -96,846,000 -9,717,000         -121,475,000  -22,036,000 -8,125,000  
          cash flows from financing activities
        		      -13,000 -260,000 -645,000  -30,000 -39,000 -743,000  -243,000 -1,570,000 -464,000  -4,257,000 369,000 -9,276,000         154,640,000 -93,832,000 49,233,000 45,035,000 45,035,000 
          proceeds from repayment on loan receivables
        		        2,678,000  2,763,000 5,139,000 6,249,000                      
          income from investments
        		                                  
          purchase of investments
        		                                  
          repayments (advances) on loan receivables
        		                                  
          gain on revaluation of derivative liabilities
        		             144,000   -10,419,000 -20,070,000 -132,916,000 -115,248,000 116,874,000 53,541,000 -105,307,000 35,880,000 -113,368,000 -571,136,000 172,440,000 -436,383,000 -436,383,000      
          gain on disposal of investments
        		                                  
          non-cash sales and marketing
        		                     358,000 347,000 337,000 1,821,000          
          advance to non-controlling interests
        		                                  
          supplementary cash flow information:
        		                                  
          accounts payable and accrued liabilities
        		              -675,000                    
          (advances) repayments on loan receivables
        		              766,000                    
          share of loss from investments in equity accounted investees
        		                 2,141,000 1,414,000   1,217,000 1,327,000     264,000  936,000     
          expected credit losses on long-term financial assets
        		                 -960,000                 
          proceeds from dissolution of joint venture
        		                44,000                  
          proceeds from repayment of loans receivable
        		                790,000                  
          share-based payments
        		                 2,420,000 2,667,000 2,565,000 2,499,000 2,463,000 7,916,000 2,546,000 2,436,000 1,123,000 1,265,000 737,000 737,000 4,238,000 273,000    
          loss on revaluation of financial instruments
        		                                  
          non-cash repurposing costs
        		                                  
          other non-cash operating activity expense
        		                                  
          proceeds from sale of investments
        		                                  
          proceeds from held-for-sale assets
        		                                  
          advances to joint ventures, net of repayments
        		                                  
          acquisition of redwood
        		                                  
          other non-cash investing activity expense
        		                                  
          proceeds from altria investment
        		                           2,434,757,000 2,434,757,000      
          proceeds from exercise of top-up rights
        		                         40,032,000         
          proceeds from exercise of warrants and options
        		                     111,000 4,000   -743,000 -432,000 1,182,000 1,182,000      
          share issuance costs
        		                         96,000 4,800,000 -4,901,000 -4,901,000 -9,577,000 6,328,000 -3,282,000 -3,081,000 -3,081,000 
          repayment of construction loan payable
        		                           -21,311,000 -21,311,000      
          advance under credit facility
        		                           65,000,000 65,000,000      
          repayment of credit facility
        		                           -65,000,000 -65,000,000      
          adjustments to reconcile net income to cash from operating activities:
        		                                  
          gain on disposal of other investments
        		                     -46,000 -3,974,000 12,000 -781,000          
          accounts payable and other liabilities
        		                  2,323,000 -737,000 -12,675,000          1,392,000    
          proceeds from sale of other investments
        		                     46,000 3,974,000 -12,000 781,000   26,078,000 26,078,000 967,000  -407,000 687,000 687,000 
          proceeds from sale of held-for-sale assets
        		                  716,000                
          inventory write-down
        		                     15,031,000 0 3,062,000 7,962,000          
          items not affecting cash:
        		                                  
          impairment loss on property, plant and equipment and right-of-use assets
        		                    1,741,000              
          expected credit losses on financial assets and non-cash charges to inventory
        		                    681,000              
          changes in non-cash working capital:
        		                                  
          proceeds from (purchase of) short-term investments
        		                                  
          other non-cash investing activities
        		                                  
          repayment of lease obligations
        		                    -613,000 -555,000 -675,000 -736,000 -448,000 -152,000 -152,000 -32,000 -32,000      
          impairment on goodwill and intangible assets
        		                                  
          provisions for inventory and doubtful accounts
        		                                  
          income tax expense
        		                             489,000     
          net changes in non-cash working capital
        		                     -4,820,000 1,447,000 -15,088,000 -15,482,000 40,864,000 -65,180,000 17,320,000 17,320,000 4,744,000     
          investments in equity accounted investees
        		                           -2,200,000 -2,200,000 -621,000     
          advances to joint ventures
        		                         5,574,000 10,331,000 -15,812,000 -15,812,000 -6,941,000     
          proceeds from share issuance
        		                             146,032,000  54,032,000 46,000,000 46,000,000 
          proceeds from construction loan payable
        		                             15,007,000     
          increase in cash and cash equivalents
        		                       -18,696,000 -71,297,000          
          impairment loss on goodwill and intangible assets
        		                      0            
          loss on unrealized foreign exchange
        		                      -1,923,000 -685,000 -412,000          
          provision for inventory and doubtful accounts
        		                                  
          loss on reclassification of held-for-sale assets
        		                                  
          other
        		                      -605,000 1,464,000 -1,157,000          
          proceeds from disposal of short-term investments
        		                      16,380,000 -3,169,000 206,847,000          
          payment of accrued interest on construction loan payable
        		                           -121,000 -121,000 -185,000     
          cash assumed on acquisition
        		                                  
          advance from non-controlling interests
        		                         127,000 -109,000 111,000 111,000      
          advance of loans payable
        		                                  
          repayment of loans payable
        		                                  
          transaction costs paid on construction loan payable
        		                                  
          provision for doubtful accounts
        		                       -631,000 2,068,000          
          cash flows provided (used) in investing activities
        		                       -19,287,000 59,086,000          
          withholding taxes paid on options
        		                                  
          cash flows provided (used) in financing activities
        		                                  
          share of net loss from investments in equity accounted investees
        		                        1,172,000          
          increase in bank indebtedness
        		                           422,000 422,000      
          withholding taxes paid on share appreciation rights
        		                         536,000 -22,000 -547,000 -547,000      
          cash flows provided (used) by financing activities
        		                        -448,000          
          items not affecting cash and cash equivalents:
        		                                  
          unrealized change in fair value of biological assets
        		                         14,039,000 9,529,000 -13,553,000 -13,553,000 -11,568,000 5,298,000    
          realized fair value adjustments on inventory sold in the period
        		                         11,060,000 -165,000 3,722,000 3,722,000  -1,114,000    
          depreciation relieved on inventory sold
        		                         1,203,000 128,000 235,000 235,000      
          gain on revaluation of financial liabilities
        		                                  
          share of loss from equity accounted investees
        		                                  
          gain on disposal of whistler
        		                           -20,606,000 -20,606,000      
          gain on other investments
        		                           -924,000 -924,000 221,000    -221,000 
          deferred income tax (recovery) expense
        		                         -3,624,000         
          foreign exchange loss
        		                           67,000       
          cash and cash equivalents from operating activities
        		                           -18,401,000       
          maturity (purchase) of short-term investments
        		                                  
          payment to exercise abcann warrants
        		                                -113,000 -113,000 
          cash and cash equivalents from investing activities
        		                           -5,439,000       
          cash and cash equivalents from financing activities
        		                           2,409,560,000       
          cash and cash equivalents - beginning of period
        		                         -838,624,000 2,385,221,000 32,634,000 32,634,000      
          effects of foreign exchange on cash and cash equivalents
        		                         982,000         
          cash and cash equivalents - end of period
        		                         -103,772,000 -839,046,000 2,418,277,000 2,418,277,000      
          the accompanying notes are an integral part of these unaudited condensed interim consolidated financial statements
        		                                  
          share of loss (income) from equity accounted investees
        		                                  
          foreign exchange gain
        		                            67,000 -11,000   -16,000 -16,000 
          cash and cash equivalents used in operating activities
        		                            -18,401,000      
          cash and cash equivalents used in investing activities
        		                            -5,439,000      
          cash and cash equivalents provided by financing activities
        		                            2,409,560,000      
          advance to cronos israel
        		                                  
          share of loss (income) from investments in equity accounted investees
        		                            264,000      
          deferred income tax expense
        		                           2,557,000 2,557,000 489,000   -888,000 -888,000 
          proceeds from shares to be issued
        		                                  
          effects of foreign exchange on cash
        		                           -77,000 -77,000      
          gross revenue
        		                             17,145,000     
          excise taxes
        		                             -1,442,000     
          net revenue
        		                             15,703,000     
          cost of sales
        		                                  
          cost of sales before fair value adjustments
        		                             7,654,000     
          gross profit before fair value adjustments
        		                             8,049,000     
          fair value adjustments
        		                                  
          realized fair value adjustments on inventory sold in the year
        		                             8,349,000     
          total fair value adjustments
        		                             -3,219,000     
          gross profit
        		                             11,268,000     
          operating expenses
        		                                  
          sales and marketing
        		                             4,111,000     
          research and development
        		                             2,350,000     
          general and administrative
        		                             17,421,000     
          total operating expenses
        		                             29,376,000     
          operating loss
        		                             -18,108,000     
          other income
        		                                  
          interest income
        		                             107,000     
          share of income from investments in equity accounted investees
        		                             -936,000     
          total other income
        		                             -608,000     
          income before income taxes
        		                             -18,716,000     
          net income attributable to:
        		                                  
          cronos group
        		                             -18,970,000     
          non-controlling interests
        		                             -235,000     
          other comprehensive income
        		                                  
          gain on revaluation and disposal of other investments, net of tax
        		                             46,000     
          foreign exchange gain on translation of foreign operations
        		                             4,000     
          unrealized gains reclassified to net income
        		                                  
          total other comprehensive income
        		                             50,000     
          comprehensive income
        		                             -19,155,000     
          comprehensive income attributable to:
        		                                  
          net income per share
        		                                  
          basic
        		                             -110     
          diluted
        		                             -110     
          weighted-average number of outstanding shares
        		                                  
          repayment of purchase price liability
        		                                  
          investment in abcann global corporation
        		                                  
          payment to exercise abcann global corporation warrants
        		                             -113,000     
          proceeds from exercise of warrants
        		                             2,800,000 312,000 -1,148,000 1,280,000 1,280,000 
          payments from share appreciation rights
        		                             -21,000     
          proceeds from exercise of options
        		                             584,000 -440,000 394,000 73,000 73,000 
          repayment of mortgage payable
        		                                  
          net change in cash
        		                             23,426,000 -105,368,000 34,081,000 23,160,000 23,160,000 
          cash - beginning of year
        		                             9,208,000     
          cash - end of year
        		                             32,634,000     
          share of income from investment in associate
        		                                  
          net changes in non-cash working capital:
        		                                  
          sales taxes receivable
        		                              -315,000    
          prepaids and other receivables
        		                              -6,678,000    
          biological assets
        		                              -1,622,000    
          accrued interest on loan receivable
        		                                  
          government remittances payable
        		                                  
          advances to related corporations
        		                                  
          cash assumed on acquisition of cronos israel
        		                                  
          proceeds received for shares to be issued
        		                                961,000 961,000 
          increase in indebtedness
        		                                  
          payment of accrued interest on construction loan
        		                                -185,000 -185,000 
          cash - beginning of period
        		                              57,241,000    
          cash - end of period
        		                              -48,127,000    
          cash flows used in investing activities
        		                                 -8,125,000 
          share of income from whistler investment
        		                                  
          deferred income tax recovery
        		                                  
          investment in whistler
        		                                  
          advances of promissory note receivable
        		                                  
          stock-based payments
        		                                774,000 774,000 
          share of income from investment in whistler
        		                                -41,000 -41,000 
          loss on other investments
        		                                -221,000  
          increase in accounts receivable
        		                                -1,386,000 -1,386,000 
          increase in sales taxes receivable
        		                                -1,152,000 -1,152,000 
          increase in prepaids and other receivables
        		                                -3,866,000 -3,866,000 
          increase in biological assets
        		                                -768,000 -768,000 
          increase in inventory
        		                                -598,000 -598,000 
          increase in accrued interest on loan receivable
        		                                  
          increase in accounts payable and other liabilities
        		                                -5,078,000 -5,078,000 
          payment of promissory note receivable
        		                                -926,000 -926,000 
          repayment of finance lease obligation
        		                                -13,000 -13,000 
          cash—beginning of period
        		                                9,208,000 9,208,000 
          cash—end of period
        		                                32,368,000 32,368,000 
          cash flows used in operating activities
        		                                 -13,750,000 
          1.